Roche: leukemia drug shows 'meaningful' improvements
(CercleFinance.com) - New data confirm that Roche's antibody Gazyva/Gazyvaro extends the lives of people with chronic lymphocytic leukaemia compared to MabThera/Rituxan, another of Roche's drugs, the Swiss drugmaker said on Friday.
After a follow-up of nearly five years, final results of a phase III trial involving 800 people showed clinically meaningful improvements with Gazyva/Gazyvaro plus chlorambucil across multiple endpoints, including progression-free survival and overall survival, Roche said.
Gazyva/Gazyvaro reduced the risk of death by 24% compared to MabThera/Rituxan, the biopharma group said.
In detail, the majority of patients treated with Gazyva/Gazyvaro are still alive after nearly five years of treatment, Roche added.
Gazyva/Gazyvaro is currently approved in over 90 countries for people with previously untreated chronic lymphocytic leukemia, the most common form of the disease.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
After a follow-up of nearly five years, final results of a phase III trial involving 800 people showed clinically meaningful improvements with Gazyva/Gazyvaro plus chlorambucil across multiple endpoints, including progression-free survival and overall survival, Roche said.
Gazyva/Gazyvaro reduced the risk of death by 24% compared to MabThera/Rituxan, the biopharma group said.
In detail, the majority of patients treated with Gazyva/Gazyvaro are still alive after nearly five years of treatment, Roche added.
Gazyva/Gazyvaro is currently approved in over 90 countries for people with previously untreated chronic lymphocytic leukemia, the most common form of the disease.
Copyright (c) 2018 CercleFinance.com. All rights reserved.